Objective-Cord blood-derived human endothelial colony-forming cells (ECFCs) bear a high proliferative capacity and potently enhance tissue neovascularization in vivo. Here, we investigated whether the leading mechanism for the functional improvement relates to their physical vascular incorporation or perivascular paracrine effects and whether the effects can be further enhanced by dual-cell-based therapy, including mesenchymal stem cells (MSCs). Methods and Results-ECFCs or MSCs were lentivirally transduced with thymidine kinase suicide gene driven by the endothelial-specific vascular endothelial growth factor 2 (kinase insert domain receptor) promoter and evaluated in a hindlimb ischemia model. ECFCs and MSCs enhanced neovascularization after ischemic events to a similar extent. Dual therapy using ECFCs and MSCs further enhanced neovascularization. Mechanistically, 3 weeks after induction of ischemia followed by cell therapy, ganciclovir-mediated elimination of kinase insert domain receptor ϩ cells completely reversed the therapeutic effect of ECFCs but not that of MSCs. Histological analysis revealed that ganciclovir effectively eliminated ECFCs incorporated into the vasculature. Conclusion-Endothelial-specific suicide gene technology demonstrates distinct mechanisms for ECFCs and MSCs, with complete abolishment of ECFC-mediated effects, whereas MSC-mediated effects remained unaffected. These data strengthen the notion that a dual-cell-based therapy represents a promising approach for vascular regeneration of ischemic tissue. (Arterioscler Thromb Vasc Biol. 2012;32:e13-e21.)Key Words: angiogenesis Ⅲ coronary heart disease Ⅲ endothelium Ⅲ ischemia Ⅲ peripheral arterial disease D iseases of the cardiovascular system remain the leading causes of mortality and still account for more deaths than cancer, chronic lower respiratory diseases, and accidents together. 1 Regenerative medicine using stem and progenitor cells from different sources is a rapidly growing area of research aiming for repair or replacement of injured tissues. Some previous cell-based therapies using adult-derived stem and progenitor cells showed significant, albeit modest functional improvements and, therefore, did not fulfill high expectations. 2 On the other hand, ethical controversy and immunologic barriers over pluripotent embryonic stem cells hindered their therapeutic application, whereas induced pluripotent cells are still in their infancy and require comprehensive characterization and complete depletion of teratogenic cells before their clinical use. Still, the future use of induced pluripotent cell-derived, patientspecific, highly proliferative ECFCs raises the question of potential security measures, such as the use of suicide genes to stop excessive proliferation.To date, cell therapy based on the use of autologous endothelial progenitor cells (EPCs) still remains a safe, promising, and innovative therapeutic approach. These cells are capable of enhancing neovascularization after ischemic insults, including limb ischemia, acute myocar...